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systematic nutritional screening was undertaken on
admission. This study demonstrates which patients
receive enteral tube feeding and estimates the hospital
burden of such patients. METHODS: The CHKS hospi-
tal dataset contains aggregated, anonymised information
on diagnosis, hospital experience, and patient demo-
graphics for over 80 million episodes in the UK, repre-
senting 55% of hospital admissions. It was used to
identify patients who received enteral nutrition (using
OPCS-4 codes) and compared their hospital stays with a
control group who had the same primary diagnoses but
were not tube fed. Both groups were analysed for comor-
bidities, procedures, and length of stay (LOS). RESULTS:
We identiﬁed 14,328 patients who were tube fed in
2001/2002 out of 947,897 patients who were hospi-
talised for various diseases/conditions: dysphagia, cancer;
stroke; neurological, respiratory and GI disorders, cystic
ﬁbrosis, feeding difﬁculties/anorexia, renal disease, and
others. Tube fed patients had 28,768 separate episodes
compared to 2,502,937 episodes for patients having the
same disease/condition who did not receive any tube
feeds. Overall, tube fed patients had one additional pro-
cedure, i.e. the tube feeding procedure, during their 
hospital stay compared to controls (average of 2.3 
procedures across disease groups for tube fed patients).
Daily tube feeding costs vary between £10.20 and
£13.18. This represents only 2.8–3.6% of the daily inpa-
tient cost of, for example, £359 in a surgical ward. CON-
CLUSIONS: Over 26,000 patients who are tube fed 
are admitted yearly in England. However the number of
patients receiving tube feeding is very restricted, even
though the cost is a small fraction of hospital costs. Does
every patient who could beneﬁt from tube feeding receive
it? If not, should tube feeding remain severely restricted
when it is known that its use could improve patients’
recovery?
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OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) computes payment for high cost new tech-
nology drugs and biologicals in the hospital outpatient
prospective payment system (OPPS) under two methods.
This study examines the results of CMS computations
over the initial thirty months of the hospital outpatient
prospective payment system. METHODS: Phase I: CMS
methods used ﬁrst for payment of high cost new tech-
nology drugs and biologicals eligible for initial pass-
through payment status and second for subsequent
expired pass-through payment status were identiﬁed.
Underlying assumptions were examined and formal
methodology evaluations were collected. Phase II: A
thirty-month time line was constructed. The assumptions
utilized for CMS changes in payment status at month one,
month nineteen and month twenty-eight were examined
and analyzed. Analyses employing descriptive statistics
identiﬁed components of payment assumptions and vari-
ations between the assumptions utilized at each of the
three time line milestones. Findings were compared to a
sample of actual CMS payments received by hospitals.
RESULTS: A database of methodology explanations,
visuals, and evaluations was created. An evolutionary
time line of CMS methodologies and underlying assump-
tions was created. Study analyses revealed a statistically
signiﬁcant differential between aggregated mean payment
amounts for the same high cost new technology drugs and
biologicals at the ﬁrst and the third milestones of the time
line. Over one-half of the affected drugs and biologicals
sustained payment rate reductions exceeding forty
percent. CONCLUSIONS: CMS payment methods and
underlying assumptions for expired pass-through drugs
and biologicals is ﬂawed. In addition, the basic hospital
drug acquisition cost assumptions made by CMS are not
consistent with actual hospital data. These ﬁndings will
be of use to economists, cost accountants, and policy
makers interested in arriving at equitable payments for
high cost new technology drugs that are essential to
modern health care in U.S. hospitals.
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OBJECTIVES: This outlines the lessons learned by the
author who is Director of one of the six units in the 
UK that undertake independent academic evaluations of
Technology Assessment Reviews for NICE. The author
provides an insiders’ view of the major issues that arise
in managing the evaluation process. METHODS: The
Liverpool TAR group assists NICE to provide guidance
on appropriate treatment for speciﬁc conditions in spe-
ciﬁc sub-groups of patients. The aim is to standardise clin-
ical practice around the most clinically and cost-effective
interventions. The aim is to spread cost-effective new
treatments more quickly across the health service to
promote successful innovation on the part of the phar-
maceutical industry. The importance of this UK initiative
goes beyond its national borders as other governments 
are guided by NICE judgements in their reimbursement
decisions and many are developing similar systems of
appraisal. RESULTS: The paper analyses the impact of
the 6-stage structure of NICE evaluation and assesses
how generalisable the process may be to other countries.
Issues underlying the targeting of NICE appraisals will
also be examined together with the challenges presented
